lazertinib
6 products
11 abstracts
2 targets
Target
EGFR T790MTarget
EGFR mutationAbstract
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.Org: Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, Medical Oncology, Regional University Hospital of Málaga, Málaga, Spain, Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, Paris-Saclay University, Gustave Roussy Cancer Center, Villejuif, France,
Abstract
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.Org: Princess Margaret Cancer Centre, Wakayama Medical University, Wakayama, Japan, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Jilin Cancer Hospital, Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research,
Abstract
Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.Org: University of Malaya Medical Centre, Hospital Umum Sarawak, Hospital Tengku Ampuan Afzan, First Affiliated Hospital of Army Medical University, Huizhou Municipal Central Hospital of Guangdong Province,
Abstract
Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2.Org: Virginia Health Specialists, Fairfax, VA, University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Janssen-Cilag Pharmaceutical, Pefki, Greece, Janssen Research & Development, Shanghai, China,
Abstract
A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease.Org: Stanford University Department of Radiation Oncology,
Abstract
Exploring the significance of MET overexpression by gene expression profiling versus immunohistochemistry in an EGFR-mutant lung cancer cohort.Org: Medanta Medicity, Gleneagles BGS Hospital, Sahyadri Hospital, HCA Healthcare UK, Metro Hospital,
Abstract
Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.Org: Gustave Roussy Cancer Center, University of Pennsylvania, National Cancer Center Hospital East, Kashiwa, Japan, Seoul National University Bundang Hospital, Yonsei University College of Medicine,
Abstract
Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.Org: Institut Curie, Saint Cloud, France, Virginia Cancer Specialists, Columbia University Medical Center, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Providence Cancer Institute,
Abstract
Prevention of amivantamab infusion related reactions with extended pre-infusion day oral steroid therapy.Org: Icon Cancer Centre, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center,
Abstract
Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).Org: Yonsei Cancer Center, Yonsei University Health System, Korea University Anam Hospital, Division of Medical Oncology, Gachon University Gil Medical Center, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Department of Internal Medicine, Division of Hematology and Medical Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine,
Abstract
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Yonsei Cancer Center, Yonsei University Health System, Yonsei University College of Medicine,
Product
amivantamab + lazertinibProduct
SC amivantamab + lazertinibProduct
LazertinibProduct
lazertinib + amivantamab